Charles Venuto, PharmD, is a clinical pharmacologist with experience in pharmacokinetic and population pharmacokinetic modeling. His main research interests focus on characterizing the pharmacokinetics and pharmacodynamics of approved and investigational drugs and identifying influential sources of variability in drug behavior. These could include: pharmacogenetics, drug-drug interactions, and disease progression factors. Dr. Venuto has collaborated with the New York State Center of Excellence Translational Pharmacology Research Core, the AIDS Clinical Trials Group, and CHDI (formerly the Cure Huntington's Disease Initiative) in various clinical pharmacology modeling and simulation projects.
Awards and Honors
American Foundation for Pharmaceutical Education Gateway to Research Scholar (2007)
Dr. Daniel H. Murray Memorial Professional Development Award, University at Buffalo School of Pharmacy and Pharmaceutical Sciences (2010)
Kelli Jordan Memorial Clinical Research Award, University at Buffalo School of Pharmacy and Pharmaceutical Sciences (2010)
Young Investigator Award, 19th Conference on Retroviruses and Opportunistic Infections (2012)
Kieburtz K, Venuto CS. TRACK-HD: both promise and disappointment. Lancet Neurology 2012; 11(1): 25-5. PMID: 22137355.
Venuto CS, McGarry A, Ma Q, Kieburtz K. Pharmacologic approaches to the treatment of Huntington Disease. Movement Disorders 2012; 27(1): 31-41. PMID: 21997232.
Ma Q, Zingman BS, Luque A, Fischl MA, Gripshover B, Venuto CS, DiFrancesco R, Forrest A, Morse GD. Therapeutic drug monitoring of protease inhibitors and efavirenz in HIV-infected individuals with active substance related disorders. Therapeutic Drug Monitoring 2011; 33(3): 309-314. PMID: 21544014.
Goodman L Sia C, Carnes R, Vetter L, Taubman F, Venuto CS, McGarry A, Kieburtz K, Agarwal P. Advocacy recruiting for Huntington's Disease clinical trials. PLoS Currents 2011; 3: RRN1230. PMID: 21532913.
Venuto C, Brown J, Butler M, Dodds EA. Alternative therapies for Clostridium difficile infection. Pharmacotherapy 2010; 30(12): 1266-78. PMID: 21114394.
Ma Q, Brazeau D, Zingman BS, Reichman RC, Fischl MA, Gripshover BM, Venuto CS, Slish JC, DiFrancesco R, Forest A, Morse GD. Multidrug Resistance 1 polymorphisms and trough concentrations of atazanavir and lopinavir in patients with HIV. Pharmacogenomics 2007; 8(3): 227-235. PMID: 17324111.
Pharm.D., State University of New York at Buffalo, 2010
B.S. Molecular Biology and Microbiology, University of Central Florida, 2006
Venuto CS, McGarry A, Ma Q, Kieburtz K. "Pharmacologic approaches to the treatment of Huntington's disease." Movement disorders : official journal of the Movement Disorder Society.. 2012 Jan; 27(1):31-41. Epub 2011 Oct 13.
Kieburtz K, Venuto C. "TRACK-HD: both promise and disappointment." The Lancet. Neurology.. 2012 Jan; 11(1):24-5. Epub 2011 Dec 02.
Ma Q, Zingman BS, Luque AE, Fischl MA, Gripshover BM, Venuto CS, DiFrancesco R, Forrest A, Morse GD. "Therapeutic drug monitoring of protease inhibitors and efavirenz in HIV-infected individuals with active substance-related disorders." Therapeutic drug monitoring.. 2011 Jun; 33(3):309-14.
Goodman L, Sia C, Carnes R, Vetter L, Taubman F, Venuto CS, McGarry A, Kieburtz K, Agarwal P. "Advocacy Recruiting for Huntington's Disease Clinical Trials." PLoS currents. 2011 3:RRN1230. Epub 2011 Apr 12.
Venuto C, Butler M, Ashley ED, Brown J. "Alternative therapies for Clostridium difficile infections." Pharmacotherapy.. 2010 30(12):1266-78.